FreeTheAI

Valion Bio Subsidiary Reaches Early Testing Benchmark for Bioprocess Monitoring

MixedLow impact
VBIO$1.27 −12.76%

Velocity Bioworks, the contract development and manufacturing subsidiary of Valion Bio, Inc. (NASDAQ:VBIO), finished an early trial testing the BioScan-NMR system from LarmorBio, Inc. The assessment confirmed that magnetic resonance readings can track bacterial growth during fermentation, closely matching standard biological density indicators.

Biopharmaceutical manufacturing usually depends on indirect measurements and physical sampling to check cell health, which risks batch contamination and slows problem identification. LarmorBio's tool is intended to deliver real-time, non-invasive observation of cell size, density, and viability directly inside bioreactors. If successfully developed, this system could help biomanufacturers catch production flaws faster, lower overall expenses, and prevent ruined batches.

Velocity Bioworks plans to apply data from this initial trial toward future development steps, focusing on continuous monitoring within sealed systems. Stock in Valion Bio traded down 6.45% at $1.45 following the release.

Key points

  • Velocity Bioworks finished an initial assessment of LarmorBio's BioScan-NMR bioprocessing platform.
  • Results showed magnetic resonance data matched standard biological measurements of microbial growth.
  • The progress occurred within six months of Valion Bio acquiring exclusive rights to the technology.
  • Valion Bio shares dropped 6.45% to $1.45 on the day of the release.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did Valion Bio announce regarding its bioprocessing platform?

Valion Bio announced that its subsidiary Velocity Bioworks completed an initial evaluation of LarmorBio's BioScan-NMR system, demonstrating its ability to monitor microbial growth during fermentation.

Why is LarmorBio's BioScan-NMR technology significant for manufacturing?

BioScan-NMR provides real-time, non-invasive tracking of cell density and viability inside bioreactors, helping manufacturers detect production issues early without opening sterile systems.

How did Valion Bio stock perform after the news?

Valion Bio (NASDAQ:VBIO) shares fell 6.45% to trade at $1.45 following the announcement.